Review



stat3 inhibitor stattic  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Santa Cruz Biotechnology stat3 inhibitor stattic
    Wwox and <t>p-STAT3</t> exhibit converse patterns of expression in breast cancer (BC) cells. a Western blotting was performed to detect p-STAT3 and Wwox levels in 12 human BC cell lines. The protein levels of p-STAT3 were detected. b 2D plots of total RNA-seq genes in Group 1 luminal cells (MCF-7, T47D, BT-474) and Group 2 basal cells (SUM159, HBL100, BT-549). Up- and downregulated genes with fold change ≥2.0 are highlighted. c KEGG pathway analysis of up-regulated genes in basal cells compared with luminal cells. d – f Western blot analysis of Wwox and p-STAT3 expression in SUM159 ( d ), HBL100 ( e ), and MDA-MB-231 cells ( f ) stably transfected with control (CT) or Wwox-encoding vectors. g , h IHC determination of Wwox and p-STAT3 expression in 90 human triple-negative BCs. Representative IHC staining images of Wwox and p-STAT3 ( g ); results are tabulated as shown ( h ); *** p < 0.001, χ 2 test, scale bar, 100 μm
    Stat3 Inhibitor Stattic, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 4462 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stat3+expression+construct/Stat3/pmc06113304-239-14-21
    Average 96 stars, based on 4462 article reviews
    stat3 inhibitor stattic - by Bioz Stars, 2026-09
    96/100 stars

    Images

    1) Product Images from "Loss of Wwox drives metastasis in triple-negative breast cancer by JAK2/STAT3 axis"

    Article Title: Loss of Wwox drives metastasis in triple-negative breast cancer by JAK2/STAT3 axis

    Journal: Nature Communications

    doi: 10.1038/s41467-018-05852-8

    Wwox and p-STAT3 exhibit converse patterns of expression in breast cancer (BC) cells. a Western blotting was performed to detect p-STAT3 and Wwox levels in 12 human BC cell lines. The protein levels of p-STAT3 were detected. b 2D plots of total RNA-seq genes in Group 1 luminal cells (MCF-7, T47D, BT-474) and Group 2 basal cells (SUM159, HBL100, BT-549). Up- and downregulated genes with fold change ≥2.0 are highlighted. c KEGG pathway analysis of up-regulated genes in basal cells compared with luminal cells. d – f Western blot analysis of Wwox and p-STAT3 expression in SUM159 ( d ), HBL100 ( e ), and MDA-MB-231 cells ( f ) stably transfected with control (CT) or Wwox-encoding vectors. g , h IHC determination of Wwox and p-STAT3 expression in 90 human triple-negative BCs. Representative IHC staining images of Wwox and p-STAT3 ( g ); results are tabulated as shown ( h ); *** p < 0.001, χ 2 test, scale bar, 100 μm
    Figure Legend Snippet: Wwox and p-STAT3 exhibit converse patterns of expression in breast cancer (BC) cells. a Western blotting was performed to detect p-STAT3 and Wwox levels in 12 human BC cell lines. The protein levels of p-STAT3 were detected. b 2D plots of total RNA-seq genes in Group 1 luminal cells (MCF-7, T47D, BT-474) and Group 2 basal cells (SUM159, HBL100, BT-549). Up- and downregulated genes with fold change ≥2.0 are highlighted. c KEGG pathway analysis of up-regulated genes in basal cells compared with luminal cells. d – f Western blot analysis of Wwox and p-STAT3 expression in SUM159 ( d ), HBL100 ( e ), and MDA-MB-231 cells ( f ) stably transfected with control (CT) or Wwox-encoding vectors. g , h IHC determination of Wwox and p-STAT3 expression in 90 human triple-negative BCs. Representative IHC staining images of Wwox and p-STAT3 ( g ); results are tabulated as shown ( h ); *** p < 0.001, χ 2 test, scale bar, 100 μm

    Techniques Used: Expressing, Western Blot, RNA Sequencing, Stable Transfection, Transfection, Control, Immunohistochemistry

    Wwox inhibits metastasis and tumor proliferation. a , b Transwell migration assays were performed with SUM159 and MDA-MB-231 cells stably transfected with control or Wwox-encoding vectors. Representative images of migrated SUM159 ( a ) and MDA-MB-231 ( b ). Quantitative results are respectively illustrated for migration in a , b . Data represent the mean ± SD ( n = 3) from three independent experiments; ** p < 0.01, Student’s t -test. Scale bar, 100 μm. c – e Wwox inhibits MDA-MB-231 proliferation in vivo. Cells of mock-transfected MDA-MB-231 and Wwox-overexpressing MDA-MB-231(Wwox OE) lines were orthotopically transplanted into the mice mammary fat pad. Tumor sizes were monitored over a period of 21 days ( d ). At necropsy, tumors were harvested, photographed ( c ), and weighed. Results are presented as mean ± SD ( n = 6) of calculated tumor weight ( e ); ** p < 0.01, Student’s t -test. Scale bar, 1 cm. f – h Liver tissues were photographed, fixed, and stained with hematoxylin and eosin (H&E) ( g ); black arrows indicate the liver metastatic lesions ( f ). The number of metastatic lesions in each specimen was counted ( h ). Results are presented as mean ± SD ( n = 6); ** p < 0.01, Student’s t -test. ( f ), Scale bar, 1 cm, ( g ) scale bar: 100 μm. i Expression of STAT3-targeted genes was examined in indicated MDA-MB-231 cells. Results shown are mean ± SD from three repeats; * p < 0.05. j Western blot analysis of the levels of p-STAT3 in MDA-MB-231 Wwox-overexpressing tumors and control tumors from orthotopic xenograft transplantation experiments
    Figure Legend Snippet: Wwox inhibits metastasis and tumor proliferation. a , b Transwell migration assays were performed with SUM159 and MDA-MB-231 cells stably transfected with control or Wwox-encoding vectors. Representative images of migrated SUM159 ( a ) and MDA-MB-231 ( b ). Quantitative results are respectively illustrated for migration in a , b . Data represent the mean ± SD ( n = 3) from three independent experiments; ** p < 0.01, Student’s t -test. Scale bar, 100 μm. c – e Wwox inhibits MDA-MB-231 proliferation in vivo. Cells of mock-transfected MDA-MB-231 and Wwox-overexpressing MDA-MB-231(Wwox OE) lines were orthotopically transplanted into the mice mammary fat pad. Tumor sizes were monitored over a period of 21 days ( d ). At necropsy, tumors were harvested, photographed ( c ), and weighed. Results are presented as mean ± SD ( n = 6) of calculated tumor weight ( e ); ** p < 0.01, Student’s t -test. Scale bar, 1 cm. f – h Liver tissues were photographed, fixed, and stained with hematoxylin and eosin (H&E) ( g ); black arrows indicate the liver metastatic lesions ( f ). The number of metastatic lesions in each specimen was counted ( h ). Results are presented as mean ± SD ( n = 6); ** p < 0.01, Student’s t -test. ( f ), Scale bar, 1 cm, ( g ) scale bar: 100 μm. i Expression of STAT3-targeted genes was examined in indicated MDA-MB-231 cells. Results shown are mean ± SD from three repeats; * p < 0.05. j Western blot analysis of the levels of p-STAT3 in MDA-MB-231 Wwox-overexpressing tumors and control tumors from orthotopic xenograft transplantation experiments

    Techniques Used: Migration, Stable Transfection, Transfection, Control, In Vivo, Staining, Expressing, Western Blot, Transplantation Assay

    Wwox inhibits STAT3 phosphorylation. a Co-immunoprecipitation of Wwox and STAT3 shows Wwox–STAT3 interaction in vivo. 293T cells were transfected with plasmids expressing Myc-tagged full-length Wwox or Flag-tagged full-length STAT3, as indicated. Whole-cell lysates were used in immunoprecipitation (IP) with anti-Myc antibody or anti-Flag M2 antibody. b Endogenous Wwox and STAT3 interact in vivo. Lysates of MCF-10A, MCF-7, and T47D cells were subjected to IP with anti-STAT3 antibodies. c , d Wwox inhibits STAT3 transcriptional activity. MCF-7 cells were co-transfected with APRE-luciferase reporter and Renilla luciferase reporter, in backgrounds providing depletion (via RNAi) of Wwox (Wwoxi) ( c ) or overexpression of Wwox (Wwox). d Relative luciferase activity data are presented as mean ± SD from three independent experiments; ** p < 0.01. e – g Wwox decreases the DNA-binding ability of STAT3. EMSA assays were performed using a biotin-labeled high-affinity binding site for STAT3. SUM159 cells were transfected with empty vector (V) or construct encoding Wwox or Wwox-Y33R mutant; MCF-7 cells were knocked down (KD) with Wwox siRNA ( e ). SUM159 or MCF-7 cells were treated with or without IL-6 for 30 min. Levels of the proteins used in EMSA are shown together with the p-STAT3 level in f , g . h , i Wwox suppresses STAT3 phoshorylation. Cells were treated with IL-6 for the indicated time intervals, using MCF-7 cells in which Wwox was knocked down (Wwox KD) or in SUM159 cells overexpressing Wwox (Wwox OE). Levels of phosphorylated STAT3 (p-STAT3) and total STAT3 were determined
    Figure Legend Snippet: Wwox inhibits STAT3 phosphorylation. a Co-immunoprecipitation of Wwox and STAT3 shows Wwox–STAT3 interaction in vivo. 293T cells were transfected with plasmids expressing Myc-tagged full-length Wwox or Flag-tagged full-length STAT3, as indicated. Whole-cell lysates were used in immunoprecipitation (IP) with anti-Myc antibody or anti-Flag M2 antibody. b Endogenous Wwox and STAT3 interact in vivo. Lysates of MCF-10A, MCF-7, and T47D cells were subjected to IP with anti-STAT3 antibodies. c , d Wwox inhibits STAT3 transcriptional activity. MCF-7 cells were co-transfected with APRE-luciferase reporter and Renilla luciferase reporter, in backgrounds providing depletion (via RNAi) of Wwox (Wwoxi) ( c ) or overexpression of Wwox (Wwox). d Relative luciferase activity data are presented as mean ± SD from three independent experiments; ** p < 0.01. e – g Wwox decreases the DNA-binding ability of STAT3. EMSA assays were performed using a biotin-labeled high-affinity binding site for STAT3. SUM159 cells were transfected with empty vector (V) or construct encoding Wwox or Wwox-Y33R mutant; MCF-7 cells were knocked down (KD) with Wwox siRNA ( e ). SUM159 or MCF-7 cells were treated with or without IL-6 for 30 min. Levels of the proteins used in EMSA are shown together with the p-STAT3 level in f , g . h , i Wwox suppresses STAT3 phoshorylation. Cells were treated with IL-6 for the indicated time intervals, using MCF-7 cells in which Wwox was knocked down (Wwox KD) or in SUM159 cells overexpressing Wwox (Wwox OE). Levels of phosphorylated STAT3 (p-STAT3) and total STAT3 were determined

    Techniques Used: Phospho-proteomics, Immunoprecipitation, In Vivo, Transfection, Expressing, Activity Assay, Luciferase, Over Expression, Binding Assay, Labeling, Plasmid Preparation, Construct, Mutagenesis

    Wwox inhibits the interaction of JAK2 and STAT3. a Co-immunoprecipitation of Wwox and JAK2 shows Wwox–JAK2 interaction. 293T cells were transfected with plasmids expressing Myc-tagged full-length Wwox or HA-tagged full-length JAK2, as indicated. Whole-cell lysates were used in immunoprecipitation (IP) with anti-Myc antibody or anti-HA antibody. b Endogenous Wwox and JAK2 interact in vivo. Lysates of MCF-10A and T47D cells were subjected to IP with anti-JAK2 antibodies. c Wwox interacts with JAK2 mainly through the WW1 domain. IP and immunoblot (IB) of cell lysates from 293T cells expressing HA-tagged STAT3 and Myc-tagged Wwox or Myc-tagged truncated Wwox proteins (illustrated in Supplementary Fig. ). Whole-cell lysates were immunoprecipitated with anti-HA and immunoblotted with anti-Myc antibody. d Wwox reduces p-STAT3 and p-JAK2 levels. MDA-MB-231 cells were transfected with Wwox plasmids and were treated with IL-6 for 30 min. The whole-cell lysates were immunoblotted with the indicated antibodies. e Interaction pattern of Wwox and JAK2 under IL-6 stimulation. IP and IB of cell lysates from 293T cells expressing HA-tagged JAK2 and Myc-tagged Wwox; cells were treated with IL-6 for the indicated time spans. f Wwox inhibits the interaction of JAK2 with STAT3. MCF-7 cells were transfected with Wwox siRNA, along with IL-6 stimulation; cell lysates were subjected to IP and IB analyses
    Figure Legend Snippet: Wwox inhibits the interaction of JAK2 and STAT3. a Co-immunoprecipitation of Wwox and JAK2 shows Wwox–JAK2 interaction. 293T cells were transfected with plasmids expressing Myc-tagged full-length Wwox or HA-tagged full-length JAK2, as indicated. Whole-cell lysates were used in immunoprecipitation (IP) with anti-Myc antibody or anti-HA antibody. b Endogenous Wwox and JAK2 interact in vivo. Lysates of MCF-10A and T47D cells were subjected to IP with anti-JAK2 antibodies. c Wwox interacts with JAK2 mainly through the WW1 domain. IP and immunoblot (IB) of cell lysates from 293T cells expressing HA-tagged STAT3 and Myc-tagged Wwox or Myc-tagged truncated Wwox proteins (illustrated in Supplementary Fig. ). Whole-cell lysates were immunoprecipitated with anti-HA and immunoblotted with anti-Myc antibody. d Wwox reduces p-STAT3 and p-JAK2 levels. MDA-MB-231 cells were transfected with Wwox plasmids and were treated with IL-6 for 30 min. The whole-cell lysates were immunoblotted with the indicated antibodies. e Interaction pattern of Wwox and JAK2 under IL-6 stimulation. IP and IB of cell lysates from 293T cells expressing HA-tagged JAK2 and Myc-tagged Wwox; cells were treated with IL-6 for the indicated time spans. f Wwox inhibits the interaction of JAK2 with STAT3. MCF-7 cells were transfected with Wwox siRNA, along with IL-6 stimulation; cell lysates were subjected to IP and IB analyses

    Techniques Used: Immunoprecipitation, Transfection, Expressing, In Vivo, Western Blot

    Wwox inhibits IL-6 induction. a Cytokine array analysis of conditioned medium (CM) from SUM159 cell culture. Equal numbers of SUM159 cells transfected with control empty vector (159 control) or with Wwox overexpression construct (159 Wwox) were seeded on culture plates and incubated in DMEM supplemented with 10% FBS for 24 h at 37 °C to allow cell attachment; culture medium was then switched to DMEM without serum. After incubation for 48 h, CM was collected and centrifuged at 2000 × g for 10 min at 4 °C to remove cell debris. The resulting supernatant was used for the experiment. b ELISA quantification of IL-6 production in the same CMs analyzed by the cytokine array in a . c IL-6 production by various luminal breast cancer (BC) cells and basal-like BC cells analyzed by ELISA compared with IL-6 production by MCF-7 cells. d Wild-type (−1000 to +1 bp with respect to the transcription start site) and truncated IL-6 promoter constructs were co-transfected with a vector encoding Wwox, and the luciferase activity was determined. e 293T cells were transfected with Wwox plasmids, and cultures were analyzed for STAT3 binding to the IL-6 promoter. Data represent the mean ± SD ( n = 3) from three independent experiments; * p < 0.05, ** p < 0.01, *** p < 0.001, Student’s t -test
    Figure Legend Snippet: Wwox inhibits IL-6 induction. a Cytokine array analysis of conditioned medium (CM) from SUM159 cell culture. Equal numbers of SUM159 cells transfected with control empty vector (159 control) or with Wwox overexpression construct (159 Wwox) were seeded on culture plates and incubated in DMEM supplemented with 10% FBS for 24 h at 37 °C to allow cell attachment; culture medium was then switched to DMEM without serum. After incubation for 48 h, CM was collected and centrifuged at 2000 × g for 10 min at 4 °C to remove cell debris. The resulting supernatant was used for the experiment. b ELISA quantification of IL-6 production in the same CMs analyzed by the cytokine array in a . c IL-6 production by various luminal breast cancer (BC) cells and basal-like BC cells analyzed by ELISA compared with IL-6 production by MCF-7 cells. d Wild-type (−1000 to +1 bp with respect to the transcription start site) and truncated IL-6 promoter constructs were co-transfected with a vector encoding Wwox, and the luciferase activity was determined. e 293T cells were transfected with Wwox plasmids, and cultures were analyzed for STAT3 binding to the IL-6 promoter. Data represent the mean ± SD ( n = 3) from three independent experiments; * p < 0.05, ** p < 0.01, *** p < 0.001, Student’s t -test

    Techniques Used: Cell Culture, Transfection, Control, Plasmid Preparation, Over Expression, Construct, Incubation, Cell Attachment Assay, Enzyme-linked Immunosorbent Assay, Luciferase, Activity Assay, Binding Assay

    The levels of Wwox expression in breast cancer (BC) have prognostic implications. a The mRNA expression profiles of Wwox in normal breast tissues and in different molecular subtypes of BC; * p < 0.05, ** p < 0.01, *** p < 0.001. Student’s t -test. b , c IHC staining for Wwox in adjacent normal and paired triple-negative BCs (TNBCs) ( b ). Box plots of Wwox protein expression assessed by blinded IHC analyses of 25 normal and paired TNBC tissues ( c ); *** p < 0.001, Student’s t -test. Scale bar, 100 μm. d Kaplan–Meier curves for overall survival in 150 human BC patients classified by relative (high or low) immune signal for Wwox protein levels. The log-rank (Mantel–Cox) test p value reflects the significance of the correlation between Wwox positivity and longer survival outcomes; *** p < 0.001, log-rank test. e The percentage of Wwox protein levels in different subtypes of 150 human BC samples. The definitions of 'high' and 'low' are given in the Methods section. f A model of the regulation of STAT3 activity by Wwox in BC. Wwox inhibits JAK2 phosphorylation and attenuates the interaction between JAK2 and STAT3, suppressing STAT3 phosphorylation and inhibiting IL-6 production
    Figure Legend Snippet: The levels of Wwox expression in breast cancer (BC) have prognostic implications. a The mRNA expression profiles of Wwox in normal breast tissues and in different molecular subtypes of BC; * p < 0.05, ** p < 0.01, *** p < 0.001. Student’s t -test. b , c IHC staining for Wwox in adjacent normal and paired triple-negative BCs (TNBCs) ( b ). Box plots of Wwox protein expression assessed by blinded IHC analyses of 25 normal and paired TNBC tissues ( c ); *** p < 0.001, Student’s t -test. Scale bar, 100 μm. d Kaplan–Meier curves for overall survival in 150 human BC patients classified by relative (high or low) immune signal for Wwox protein levels. The log-rank (Mantel–Cox) test p value reflects the significance of the correlation between Wwox positivity and longer survival outcomes; *** p < 0.001, log-rank test. e The percentage of Wwox protein levels in different subtypes of 150 human BC samples. The definitions of 'high' and 'low' are given in the Methods section. f A model of the regulation of STAT3 activity by Wwox in BC. Wwox inhibits JAK2 phosphorylation and attenuates the interaction between JAK2 and STAT3, suppressing STAT3 phosphorylation and inhibiting IL-6 production

    Techniques Used: Expressing, Immunohistochemistry, Activity Assay, Phospho-proteomics



    Similar Products

    96
    OriGene stat3 expression construct
    Stat3 Expression Construct, supplied by OriGene, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stat3+expression+construct/pCMV6-XL4+Mammalian+Expression+Vector/pm42162632-58-3-16
    Average 96 stars, based on 1 article reviews
    stat3 expression construct - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    93
    Addgene inc stat3 expression construct plegfp wt stat3 oncogene
    Stat3 Expression Construct Plegfp Wt Stat3 Oncogene, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stat3+expression+construct/pLEGFP-WT-STAT3+(Plasmid+%2371450)/pm40247082-88-0-8
    Average 93 stars, based on 1 article reviews
    stat3 expression construct plegfp wt stat3 oncogene - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    90
    Shanghai Genechem Ltd lentiviral expression constructs human stat3
    A , B Role of <t>ELK1,</t> STAT3 and SRF in regulating the transcriptional activity of MCL1 under basal conditions and in response to HER2-targeting drugs. SNU-216 cells expressing empty vector or the indicated transcriptional factors were left untreated or treated with 100 ng/ml trastuzumab ( A ) or 200 nM lapatinib ( B ) for 72 h or 48 h, respectively. The levels of MCL1 mRNA were determined using RT-qPCR. C Effect of HER2-targeting drugs on STAT3 and SRF expression. SNU-216, NCI-N87 and GCIY were treated with 100 ng/ml trastuzumab or 200 nM lapatinib for 72 h or 48 h, respectively. The protein levels of p-STAT3, total STAT3, and SRF were determined by Western blotting. D , E Dual luciferase reporter assays to identify the binding site(s) of STAT3 and SRF in the MCL1 promoter. Left: diagram depicting the putative binding sites of STAT3 ( D ) or SRF ( E ) in the MCL1 promoter predicted by the JASPAR database. Right: Dual luciferase reporter assays conducted in HEK293T. F Reduced binding of STATS and SRF in the MCL1 promoter upon HER2-targeting drug treatments. SNU-216 cells were left untreated or treated with 100 ng/ml trastuzumab or 200 nM lapatinib for 72 h or 48 h, respectively. ChIP was conducted using specific antibodies against STAT3, SRF, and an IgG isotype control. G Co-IP analysis of the interaction of endogenous STAT3 and SRF in SNU-216 cells. H Direct interaction of exogenous STAT3 and SRF. HEK293T cells were transiently transfected with HA-tagged STAT3, Flag-tagged SRF, either individually or both. Equivalent lysates were immunoprecipitated with anti-HA or anti-Flag antibody and immunoblotted with the indicated antibodies. I Effect of overexpressing or deleting STAT3 on SRF expression. The mRNA (left) and protein (right) levels of SRF in SNU-216 cells with STAT3 overexpression or depletion were determined. J Similar experiments to those in panel I were conducted to detect the effect of manipulating SRF on STAT3 expression in SNU-216 cells. K Reduced binding of STAT3 in the SRF promoter upon HER2-targeting drug treatments. Similar experiments to those in ( F ) were conducted. L Depletion of STAT3 attenuated the binding of SRF in the MCL1 promoter. Similar experiments to those in ( F ) were performed in SNU-216 cells engineered to express sg STAT3 . ChIP was conducted at 72 h after addition of DOX to induce the deletion of STAT3 . 2 sgRNAs were tested. M , N Deleting STAT3 enhanced the sensitivity of GC lines to BCLXL inhibition. SNU-216 ( M ) and GCIY ( N ) cells inducibly expressing sg STAT3 or the sgRNA empty vector were treated with DOX alone, or in combination with indicated concentrations of BCLXLi. Cell viability was determined 48 h later. Two-way ANOVA was used for statistical significance. O STAT3 inhibitor synergized with BCLXLi in GC cell lines, regardless of their p-STAT3 levels. GC cell lines with high p-STAT3 levels (HGC-27, MKN45 and AGS) and the ones with low p-STAT3 levels (SNU-216, NCI-N87, GCIY) were treated with indicated concentrations of BCLXLi and STAT3 inhibitor and cell viability was determined 48 h later. Data in ( A ), ( B ), ( D ), ( E ), ( I , left ), ( J , left ), ( M – O ) represent the means ± SD of ≥3 independent experiments; data in panel ( C ), ( F – H ), ( I , right ), ( J , right ), ( K ) and ( L ) are representatives of 2 independent experiments.
    Lentiviral Expression Constructs Human Stat3, supplied by Shanghai Genechem Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stat3+expression+construct/pcdna3+1/pmc11904182-358-6-35
    Average 90 stars, based on 1 article reviews
    lentiviral expression constructs human stat3 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Genechem stat3-expression construct nm_139276
    A , B Role of <t>ELK1,</t> STAT3 and SRF in regulating the transcriptional activity of MCL1 under basal conditions and in response to HER2-targeting drugs. SNU-216 cells expressing empty vector or the indicated transcriptional factors were left untreated or treated with 100 ng/ml trastuzumab ( A ) or 200 nM lapatinib ( B ) for 72 h or 48 h, respectively. The levels of MCL1 mRNA were determined using RT-qPCR. C Effect of HER2-targeting drugs on STAT3 and SRF expression. SNU-216, NCI-N87 and GCIY were treated with 100 ng/ml trastuzumab or 200 nM lapatinib for 72 h or 48 h, respectively. The protein levels of p-STAT3, total STAT3, and SRF were determined by Western blotting. D , E Dual luciferase reporter assays to identify the binding site(s) of STAT3 and SRF in the MCL1 promoter. Left: diagram depicting the putative binding sites of STAT3 ( D ) or SRF ( E ) in the MCL1 promoter predicted by the JASPAR database. Right: Dual luciferase reporter assays conducted in HEK293T. F Reduced binding of STATS and SRF in the MCL1 promoter upon HER2-targeting drug treatments. SNU-216 cells were left untreated or treated with 100 ng/ml trastuzumab or 200 nM lapatinib for 72 h or 48 h, respectively. ChIP was conducted using specific antibodies against STAT3, SRF, and an IgG isotype control. G Co-IP analysis of the interaction of endogenous STAT3 and SRF in SNU-216 cells. H Direct interaction of exogenous STAT3 and SRF. HEK293T cells were transiently transfected with HA-tagged STAT3, Flag-tagged SRF, either individually or both. Equivalent lysates were immunoprecipitated with anti-HA or anti-Flag antibody and immunoblotted with the indicated antibodies. I Effect of overexpressing or deleting STAT3 on SRF expression. The mRNA (left) and protein (right) levels of SRF in SNU-216 cells with STAT3 overexpression or depletion were determined. J Similar experiments to those in panel I were conducted to detect the effect of manipulating SRF on STAT3 expression in SNU-216 cells. K Reduced binding of STAT3 in the SRF promoter upon HER2-targeting drug treatments. Similar experiments to those in ( F ) were conducted. L Depletion of STAT3 attenuated the binding of SRF in the MCL1 promoter. Similar experiments to those in ( F ) were performed in SNU-216 cells engineered to express sg STAT3 . ChIP was conducted at 72 h after addition of DOX to induce the deletion of STAT3 . 2 sgRNAs were tested. M , N Deleting STAT3 enhanced the sensitivity of GC lines to BCLXL inhibition. SNU-216 ( M ) and GCIY ( N ) cells inducibly expressing sg STAT3 or the sgRNA empty vector were treated with DOX alone, or in combination with indicated concentrations of BCLXLi. Cell viability was determined 48 h later. Two-way ANOVA was used for statistical significance. O STAT3 inhibitor synergized with BCLXLi in GC cell lines, regardless of their p-STAT3 levels. GC cell lines with high p-STAT3 levels (HGC-27, MKN45 and AGS) and the ones with low p-STAT3 levels (SNU-216, NCI-N87, GCIY) were treated with indicated concentrations of BCLXLi and STAT3 inhibitor and cell viability was determined 48 h later. Data in ( A ), ( B ), ( D ), ( E ), ( I , left ), ( J , left ), ( M – O ) represent the means ± SD of ≥3 independent experiments; data in panel ( C ), ( F – H ), ( I , right ), ( J , right ), ( K ) and ( L ) are representatives of 2 independent experiments.
    Stat3 Expression Construct Nm 139276, supplied by Genechem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stat3+expression+construct/stat3+shrna/pmc11008271-159-0-13
    Average 90 stars, based on 1 article reviews
    stat3-expression construct nm_139276 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology shrna stat3 expressing vectors construction
    A , B Role of <t>ELK1,</t> STAT3 and SRF in regulating the transcriptional activity of MCL1 under basal conditions and in response to HER2-targeting drugs. SNU-216 cells expressing empty vector or the indicated transcriptional factors were left untreated or treated with 100 ng/ml trastuzumab ( A ) or 200 nM lapatinib ( B ) for 72 h or 48 h, respectively. The levels of MCL1 mRNA were determined using RT-qPCR. C Effect of HER2-targeting drugs on STAT3 and SRF expression. SNU-216, NCI-N87 and GCIY were treated with 100 ng/ml trastuzumab or 200 nM lapatinib for 72 h or 48 h, respectively. The protein levels of p-STAT3, total STAT3, and SRF were determined by Western blotting. D , E Dual luciferase reporter assays to identify the binding site(s) of STAT3 and SRF in the MCL1 promoter. Left: diagram depicting the putative binding sites of STAT3 ( D ) or SRF ( E ) in the MCL1 promoter predicted by the JASPAR database. Right: Dual luciferase reporter assays conducted in HEK293T. F Reduced binding of STATS and SRF in the MCL1 promoter upon HER2-targeting drug treatments. SNU-216 cells were left untreated or treated with 100 ng/ml trastuzumab or 200 nM lapatinib for 72 h or 48 h, respectively. ChIP was conducted using specific antibodies against STAT3, SRF, and an IgG isotype control. G Co-IP analysis of the interaction of endogenous STAT3 and SRF in SNU-216 cells. H Direct interaction of exogenous STAT3 and SRF. HEK293T cells were transiently transfected with HA-tagged STAT3, Flag-tagged SRF, either individually or both. Equivalent lysates were immunoprecipitated with anti-HA or anti-Flag antibody and immunoblotted with the indicated antibodies. I Effect of overexpressing or deleting STAT3 on SRF expression. The mRNA (left) and protein (right) levels of SRF in SNU-216 cells with STAT3 overexpression or depletion were determined. J Similar experiments to those in panel I were conducted to detect the effect of manipulating SRF on STAT3 expression in SNU-216 cells. K Reduced binding of STAT3 in the SRF promoter upon HER2-targeting drug treatments. Similar experiments to those in ( F ) were conducted. L Depletion of STAT3 attenuated the binding of SRF in the MCL1 promoter. Similar experiments to those in ( F ) were performed in SNU-216 cells engineered to express sg STAT3 . ChIP was conducted at 72 h after addition of DOX to induce the deletion of STAT3 . 2 sgRNAs were tested. M , N Deleting STAT3 enhanced the sensitivity of GC lines to BCLXL inhibition. SNU-216 ( M ) and GCIY ( N ) cells inducibly expressing sg STAT3 or the sgRNA empty vector were treated with DOX alone, or in combination with indicated concentrations of BCLXLi. Cell viability was determined 48 h later. Two-way ANOVA was used for statistical significance. O STAT3 inhibitor synergized with BCLXLi in GC cell lines, regardless of their p-STAT3 levels. GC cell lines with high p-STAT3 levels (HGC-27, MKN45 and AGS) and the ones with low p-STAT3 levels (SNU-216, NCI-N87, GCIY) were treated with indicated concentrations of BCLXLi and STAT3 inhibitor and cell viability was determined 48 h later. Data in ( A ), ( B ), ( D ), ( E ), ( I , left ), ( J , left ), ( M – O ) represent the means ± SD of ≥3 independent experiments; data in panel ( C ), ( F – H ), ( I , right ), ( J , right ), ( K ) and ( L ) are representatives of 2 independent experiments.
    Shrna Stat3 Expressing Vectors Construction, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stat3+expression+construct/Stat3/ppr0746723-65-0-15
    Average 96 stars, based on 1 article reviews
    shrna stat3 expressing vectors construction - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    OriGene green fluorescence protein gfp labeled stat3 expression construct
    Figure 2. Analysis of <t>STAT3</t> in HL cell lines. (A) RQ-PCR analysis of STAT3 in eight HL cell lines (left). Western blot analysis of three HL cell lines for STAT3, phospho (P)-STAT3 and alpha-tubulin (TUBA) as control (right). (B) Immuno-cytological microscopy of untreated AM-HLH cells (left) stained for STAT3 (green) and the nucleus (blue). Forced expression of GFP-labeled STAT3 in transfected AM- HLH (right). White arrowheads indicate transfected nuclei demonstrating reduced STAT3 protein in the nucleus as compared to the cytoplasm. The light blue arrowhead indicates a non-transfected cell. (C) Western blot analysis of IL6-treated AM-HLH for STAT3, P-STAT3 and TUBA (left). Immuno- cytological microscopy of IL6-treated AM-HLH cells stained for STAT3 (green) and the nucleus (blue) (middle). RQ-PCR analysis of HLX in IL6-treated AM-HLH after 4 h (right). (D) Immuno-cytological microscopy of control and TSA-treated L-540 cells stained for STAT3 (green) and the nucleus (blue). (E) RQ-PCR analysis of HLX in L-540 (left) AM-HLH (right) treated with TSA. Statistical significance was assessed by t-test and derived p-values indicated by asterisks (** p < 0.01, *** p < 0.001, n.s., not significant).
    Green Fluorescence Protein Gfp Labeled Stat3 Expression Construct, supplied by OriGene, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stat3+expression+construct/pCMV6-XL4+Mammalian+Expression+Vector/pm35884913-46-1-16
    Average 96 stars, based on 1 article reviews
    green fluorescence protein gfp labeled stat3 expression construct - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    93
    Addgene inc flag stat3c catalog 8722 expression constructs
    Figure 2. Analysis of <t>STAT3</t> in HL cell lines. (A) RQ-PCR analysis of STAT3 in eight HL cell lines (left). Western blot analysis of three HL cell lines for STAT3, phospho (P)-STAT3 and alpha-tubulin (TUBA) as control (right). (B) Immuno-cytological microscopy of untreated AM-HLH cells (left) stained for STAT3 (green) and the nucleus (blue). Forced expression of GFP-labeled STAT3 in transfected AM- HLH (right). White arrowheads indicate transfected nuclei demonstrating reduced STAT3 protein in the nucleus as compared to the cytoplasm. The light blue arrowhead indicates a non-transfected cell. (C) Western blot analysis of IL6-treated AM-HLH for STAT3, P-STAT3 and TUBA (left). Immuno- cytological microscopy of IL6-treated AM-HLH cells stained for STAT3 (green) and the nucleus (blue) (middle). RQ-PCR analysis of HLX in IL6-treated AM-HLH after 4 h (right). (D) Immuno-cytological microscopy of control and TSA-treated L-540 cells stained for STAT3 (green) and the nucleus (blue). (E) RQ-PCR analysis of HLX in L-540 (left) AM-HLH (right) treated with TSA. Statistical significance was assessed by t-test and derived p-values indicated by asterisks (** p < 0.01, *** p < 0.001, n.s., not significant).
    Flag Stat3c Catalog 8722 Expression Constructs, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stat3+expression+construct/Stat3-C+Flag+pRc%2FCMV+(Plasmid+%238722)/10__1172_slash_jci134217-286-7-15
    Average 93 stars, based on 1 article reviews
    flag stat3c catalog 8722 expression constructs - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    90
    Addgene inc constitutively active stat3 expression construct stat3-c flag prc/cmv
    Shikonin inhibited <t>STAT3</t> signaling pathway in melanoma cells. (A) Cells were treated with indicated concentration of shikonin for 24 h, expression levels of STAT3 and p-STAT3 were determined by the Western blot analysis (upper), and relative expression levels were analyzed by Image J software (bottom). (B) Cells were treated with 2 μM shikonin for 24 h, and then incubated with DSS. Changes in STAT3 dimerization were evaluated by immunoblotting. The arrows indicated the dimer (D) and the monomer (M) STAT3. The representative results (upper) and the relative expression levels of dimer STAT3 (bottom) were shown. (C, D) Cells were treated with indicated concentration of shikonin for 24 h, and then the intracellular distribution of STAT3 was analyzed by immunofluorescence assay (C) and immunoblotting (D) . Relative expression levels of cytosolic and nuclear STAT3 were also shown (bottom). Data were shown as mean ± SD from three independent experiments, * P < 0.05 and ** P < 0.01.
    Constitutively Active Stat3 Expression Construct Stat3 C Flag Prc/Cmv, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stat3+expression+construct/stat3+cdna+kiaa1524/pmc07267064-85-1-11
    Average 90 stars, based on 1 article reviews
    constitutively active stat3 expression construct stat3-c flag prc/cmv - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Addgene inc construct expressing constitutively active stat3 mutant pstat3-c
    Shikonin inhibited <t>STAT3</t> signaling pathway in melanoma cells. (A) Cells were treated with indicated concentration of shikonin for 24 h, expression levels of STAT3 and p-STAT3 were determined by the Western blot analysis (upper), and relative expression levels were analyzed by Image J software (bottom). (B) Cells were treated with 2 μM shikonin for 24 h, and then incubated with DSS. Changes in STAT3 dimerization were evaluated by immunoblotting. The arrows indicated the dimer (D) and the monomer (M) STAT3. The representative results (upper) and the relative expression levels of dimer STAT3 (bottom) were shown. (C, D) Cells were treated with indicated concentration of shikonin for 24 h, and then the intracellular distribution of STAT3 was analyzed by immunofluorescence assay (C) and immunoblotting (D) . Relative expression levels of cytosolic and nuclear STAT3 were also shown (bottom). Data were shown as mean ± SD from three independent experiments, * P < 0.05 and ** P < 0.01.
    Construct Expressing Constitutively Active Stat3 Mutant Pstat3 C, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stat3+expression+construct/stat3+cdna+kiaa1524/pm29901084-53-4-14
    Average 90 stars, based on 1 article reviews
    construct expressing constitutively active stat3 mutant pstat3-c - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    Image Search Results


    A , B Role of ELK1, STAT3 and SRF in regulating the transcriptional activity of MCL1 under basal conditions and in response to HER2-targeting drugs. SNU-216 cells expressing empty vector or the indicated transcriptional factors were left untreated or treated with 100 ng/ml trastuzumab ( A ) or 200 nM lapatinib ( B ) for 72 h or 48 h, respectively. The levels of MCL1 mRNA were determined using RT-qPCR. C Effect of HER2-targeting drugs on STAT3 and SRF expression. SNU-216, NCI-N87 and GCIY were treated with 100 ng/ml trastuzumab or 200 nM lapatinib for 72 h or 48 h, respectively. The protein levels of p-STAT3, total STAT3, and SRF were determined by Western blotting. D , E Dual luciferase reporter assays to identify the binding site(s) of STAT3 and SRF in the MCL1 promoter. Left: diagram depicting the putative binding sites of STAT3 ( D ) or SRF ( E ) in the MCL1 promoter predicted by the JASPAR database. Right: Dual luciferase reporter assays conducted in HEK293T. F Reduced binding of STATS and SRF in the MCL1 promoter upon HER2-targeting drug treatments. SNU-216 cells were left untreated or treated with 100 ng/ml trastuzumab or 200 nM lapatinib for 72 h or 48 h, respectively. ChIP was conducted using specific antibodies against STAT3, SRF, and an IgG isotype control. G Co-IP analysis of the interaction of endogenous STAT3 and SRF in SNU-216 cells. H Direct interaction of exogenous STAT3 and SRF. HEK293T cells were transiently transfected with HA-tagged STAT3, Flag-tagged SRF, either individually or both. Equivalent lysates were immunoprecipitated with anti-HA or anti-Flag antibody and immunoblotted with the indicated antibodies. I Effect of overexpressing or deleting STAT3 on SRF expression. The mRNA (left) and protein (right) levels of SRF in SNU-216 cells with STAT3 overexpression or depletion were determined. J Similar experiments to those in panel I were conducted to detect the effect of manipulating SRF on STAT3 expression in SNU-216 cells. K Reduced binding of STAT3 in the SRF promoter upon HER2-targeting drug treatments. Similar experiments to those in ( F ) were conducted. L Depletion of STAT3 attenuated the binding of SRF in the MCL1 promoter. Similar experiments to those in ( F ) were performed in SNU-216 cells engineered to express sg STAT3 . ChIP was conducted at 72 h after addition of DOX to induce the deletion of STAT3 . 2 sgRNAs were tested. M , N Deleting STAT3 enhanced the sensitivity of GC lines to BCLXL inhibition. SNU-216 ( M ) and GCIY ( N ) cells inducibly expressing sg STAT3 or the sgRNA empty vector were treated with DOX alone, or in combination with indicated concentrations of BCLXLi. Cell viability was determined 48 h later. Two-way ANOVA was used for statistical significance. O STAT3 inhibitor synergized with BCLXLi in GC cell lines, regardless of their p-STAT3 levels. GC cell lines with high p-STAT3 levels (HGC-27, MKN45 and AGS) and the ones with low p-STAT3 levels (SNU-216, NCI-N87, GCIY) were treated with indicated concentrations of BCLXLi and STAT3 inhibitor and cell viability was determined 48 h later. Data in ( A ), ( B ), ( D ), ( E ), ( I , left ), ( J , left ), ( M – O ) represent the means ± SD of ≥3 independent experiments; data in panel ( C ), ( F – H ), ( I , right ), ( J , right ), ( K ) and ( L ) are representatives of 2 independent experiments.

    Journal: Cell Death & Disease

    Article Title: Both direct and indirect suppression of MCL1 synergizes with BCLXL inhibition in preclinical models of gastric cancer

    doi: 10.1038/s41419-025-07481-8

    Figure Lengend Snippet: A , B Role of ELK1, STAT3 and SRF in regulating the transcriptional activity of MCL1 under basal conditions and in response to HER2-targeting drugs. SNU-216 cells expressing empty vector or the indicated transcriptional factors were left untreated or treated with 100 ng/ml trastuzumab ( A ) or 200 nM lapatinib ( B ) for 72 h or 48 h, respectively. The levels of MCL1 mRNA were determined using RT-qPCR. C Effect of HER2-targeting drugs on STAT3 and SRF expression. SNU-216, NCI-N87 and GCIY were treated with 100 ng/ml trastuzumab or 200 nM lapatinib for 72 h or 48 h, respectively. The protein levels of p-STAT3, total STAT3, and SRF were determined by Western blotting. D , E Dual luciferase reporter assays to identify the binding site(s) of STAT3 and SRF in the MCL1 promoter. Left: diagram depicting the putative binding sites of STAT3 ( D ) or SRF ( E ) in the MCL1 promoter predicted by the JASPAR database. Right: Dual luciferase reporter assays conducted in HEK293T. F Reduced binding of STATS and SRF in the MCL1 promoter upon HER2-targeting drug treatments. SNU-216 cells were left untreated or treated with 100 ng/ml trastuzumab or 200 nM lapatinib for 72 h or 48 h, respectively. ChIP was conducted using specific antibodies against STAT3, SRF, and an IgG isotype control. G Co-IP analysis of the interaction of endogenous STAT3 and SRF in SNU-216 cells. H Direct interaction of exogenous STAT3 and SRF. HEK293T cells were transiently transfected with HA-tagged STAT3, Flag-tagged SRF, either individually or both. Equivalent lysates were immunoprecipitated with anti-HA or anti-Flag antibody and immunoblotted with the indicated antibodies. I Effect of overexpressing or deleting STAT3 on SRF expression. The mRNA (left) and protein (right) levels of SRF in SNU-216 cells with STAT3 overexpression or depletion were determined. J Similar experiments to those in panel I were conducted to detect the effect of manipulating SRF on STAT3 expression in SNU-216 cells. K Reduced binding of STAT3 in the SRF promoter upon HER2-targeting drug treatments. Similar experiments to those in ( F ) were conducted. L Depletion of STAT3 attenuated the binding of SRF in the MCL1 promoter. Similar experiments to those in ( F ) were performed in SNU-216 cells engineered to express sg STAT3 . ChIP was conducted at 72 h after addition of DOX to induce the deletion of STAT3 . 2 sgRNAs were tested. M , N Deleting STAT3 enhanced the sensitivity of GC lines to BCLXL inhibition. SNU-216 ( M ) and GCIY ( N ) cells inducibly expressing sg STAT3 or the sgRNA empty vector were treated with DOX alone, or in combination with indicated concentrations of BCLXLi. Cell viability was determined 48 h later. Two-way ANOVA was used for statistical significance. O STAT3 inhibitor synergized with BCLXLi in GC cell lines, regardless of their p-STAT3 levels. GC cell lines with high p-STAT3 levels (HGC-27, MKN45 and AGS) and the ones with low p-STAT3 levels (SNU-216, NCI-N87, GCIY) were treated with indicated concentrations of BCLXLi and STAT3 inhibitor and cell viability was determined 48 h later. Data in ( A ), ( B ), ( D ), ( E ), ( I , left ), ( J , left ), ( M – O ) represent the means ± SD of ≥3 independent experiments; data in panel ( C ), ( F – H ), ( I , right ), ( J , right ), ( K ) and ( L ) are representatives of 2 independent experiments.

    Article Snippet: The GV492 lentiviral expression constructs of human ELK1, ELK3, ELK4, STAT3, SRF, as well as the GV366 (C-terminally HA-tagged) and GV657 (C-terminally Flag-tagged) constructs for transient expression of human STAT3 and SRF were purchased from Shanghai Genechem Co., Ltd.

    Techniques: Activity Assay, Expressing, Plasmid Preparation, Quantitative RT-PCR, Western Blot, Luciferase, Binding Assay, Control, Co-Immunoprecipitation Assay, Transfection, Immunoprecipitation, Over Expression, Inhibition

    Figure 2. Analysis of STAT3 in HL cell lines. (A) RQ-PCR analysis of STAT3 in eight HL cell lines (left). Western blot analysis of three HL cell lines for STAT3, phospho (P)-STAT3 and alpha-tubulin (TUBA) as control (right). (B) Immuno-cytological microscopy of untreated AM-HLH cells (left) stained for STAT3 (green) and the nucleus (blue). Forced expression of GFP-labeled STAT3 in transfected AM- HLH (right). White arrowheads indicate transfected nuclei demonstrating reduced STAT3 protein in the nucleus as compared to the cytoplasm. The light blue arrowhead indicates a non-transfected cell. (C) Western blot analysis of IL6-treated AM-HLH for STAT3, P-STAT3 and TUBA (left). Immuno- cytological microscopy of IL6-treated AM-HLH cells stained for STAT3 (green) and the nucleus (blue) (middle). RQ-PCR analysis of HLX in IL6-treated AM-HLH after 4 h (right). (D) Immuno-cytological microscopy of control and TSA-treated L-540 cells stained for STAT3 (green) and the nucleus (blue). (E) RQ-PCR analysis of HLX in L-540 (left) AM-HLH (right) treated with TSA. Statistical significance was assessed by t-test and derived p-values indicated by asterisks (** p < 0.01, *** p < 0.001, n.s., not significant).

    Journal: Biomedicines

    Article Title: Downregulation of STAT3 in Epstein-Barr Virus-Positive Hodgkin Lymphoma.

    doi: 10.3390/biomedicines10071608

    Figure Lengend Snippet: Figure 2. Analysis of STAT3 in HL cell lines. (A) RQ-PCR analysis of STAT3 in eight HL cell lines (left). Western blot analysis of three HL cell lines for STAT3, phospho (P)-STAT3 and alpha-tubulin (TUBA) as control (right). (B) Immuno-cytological microscopy of untreated AM-HLH cells (left) stained for STAT3 (green) and the nucleus (blue). Forced expression of GFP-labeled STAT3 in transfected AM- HLH (right). White arrowheads indicate transfected nuclei demonstrating reduced STAT3 protein in the nucleus as compared to the cytoplasm. The light blue arrowhead indicates a non-transfected cell. (C) Western blot analysis of IL6-treated AM-HLH for STAT3, P-STAT3 and TUBA (left). Immuno- cytological microscopy of IL6-treated AM-HLH cells stained for STAT3 (green) and the nucleus (blue) (middle). RQ-PCR analysis of HLX in IL6-treated AM-HLH after 4 h (right). (D) Immuno-cytological microscopy of control and TSA-treated L-540 cells stained for STAT3 (green) and the nucleus (blue). (E) RQ-PCR analysis of HLX in L-540 (left) AM-HLH (right) treated with TSA. Statistical significance was assessed by t-test and derived p-values indicated by asterisks (** p < 0.01, *** p < 0.001, n.s., not significant).

    Article Snippet: A green fluorescence protein (GFP)-labeled STAT3 expression construct was cloned into vector pCMV6-XL4 and obtained from Origene (Wiesbaden, Germany).

    Techniques: Western Blot, Control, Microscopy, Staining, Expressing, Labeling, Transfection, Derivative Assay

    Figure 4. Knockdown and stimulation studies in AM-HLH and L-540. (A) SiRNA-mediated knock- down of IRF4 in AM-HLH resulted in elevated expression of STAT3 as analyzed by RQ-PCR (left). The

    Journal: Biomedicines

    Article Title: Downregulation of STAT3 in Epstein-Barr Virus-Positive Hodgkin Lymphoma.

    doi: 10.3390/biomedicines10071608

    Figure Lengend Snippet: Figure 4. Knockdown and stimulation studies in AM-HLH and L-540. (A) SiRNA-mediated knock- down of IRF4 in AM-HLH resulted in elevated expression of STAT3 as analyzed by RQ-PCR (left). The

    Article Snippet: A green fluorescence protein (GFP)-labeled STAT3 expression construct was cloned into vector pCMV6-XL4 and obtained from Origene (Wiesbaden, Germany).

    Techniques: Knockdown, Expressing

    Figure 6. Summary of the results from this study showing a gene regulatory network around STAT3. Genomic amplifications targeting particular genes are highlighted by a red background. Elevated genes are indicated in red, low level expressed genes in green while medium level expressed genes are shown in black. Functional consequences including immune escape, EBV activity, proliferation and survival are highlighted by a blue background. Bold lines indicate relationships demonstrated in this study while slight lines refer to published data.

    Journal: Biomedicines

    Article Title: Downregulation of STAT3 in Epstein-Barr Virus-Positive Hodgkin Lymphoma.

    doi: 10.3390/biomedicines10071608

    Figure Lengend Snippet: Figure 6. Summary of the results from this study showing a gene regulatory network around STAT3. Genomic amplifications targeting particular genes are highlighted by a red background. Elevated genes are indicated in red, low level expressed genes in green while medium level expressed genes are shown in black. Functional consequences including immune escape, EBV activity, proliferation and survival are highlighted by a blue background. Bold lines indicate relationships demonstrated in this study while slight lines refer to published data.

    Article Snippet: A green fluorescence protein (GFP)-labeled STAT3 expression construct was cloned into vector pCMV6-XL4 and obtained from Origene (Wiesbaden, Germany).

    Techniques: Functional Assay, Activity Assay

    Shikonin inhibited STAT3 signaling pathway in melanoma cells. (A) Cells were treated with indicated concentration of shikonin for 24 h, expression levels of STAT3 and p-STAT3 were determined by the Western blot analysis (upper), and relative expression levels were analyzed by Image J software (bottom). (B) Cells were treated with 2 μM shikonin for 24 h, and then incubated with DSS. Changes in STAT3 dimerization were evaluated by immunoblotting. The arrows indicated the dimer (D) and the monomer (M) STAT3. The representative results (upper) and the relative expression levels of dimer STAT3 (bottom) were shown. (C, D) Cells were treated with indicated concentration of shikonin for 24 h, and then the intracellular distribution of STAT3 was analyzed by immunofluorescence assay (C) and immunoblotting (D) . Relative expression levels of cytosolic and nuclear STAT3 were also shown (bottom). Data were shown as mean ± SD from three independent experiments, * P < 0.05 and ** P < 0.01.

    Journal: Frontiers in Pharmacology

    Article Title: Inhibition of the STAT3 Signaling Pathway Contributes to the Anti-Melanoma Activities of Shikonin

    doi: 10.3389/fphar.2020.00748

    Figure Lengend Snippet: Shikonin inhibited STAT3 signaling pathway in melanoma cells. (A) Cells were treated with indicated concentration of shikonin for 24 h, expression levels of STAT3 and p-STAT3 were determined by the Western blot analysis (upper), and relative expression levels were analyzed by Image J software (bottom). (B) Cells were treated with 2 μM shikonin for 24 h, and then incubated with DSS. Changes in STAT3 dimerization were evaluated by immunoblotting. The arrows indicated the dimer (D) and the monomer (M) STAT3. The representative results (upper) and the relative expression levels of dimer STAT3 (bottom) were shown. (C, D) Cells were treated with indicated concentration of shikonin for 24 h, and then the intracellular distribution of STAT3 was analyzed by immunofluorescence assay (C) and immunoblotting (D) . Relative expression levels of cytosolic and nuclear STAT3 were also shown (bottom). Data were shown as mean ± SD from three independent experiments, * P < 0.05 and ** P < 0.01.

    Article Snippet: Constitutively active STAT3 expression construct STAT3-C Flag pRc/CMV was obtained from Addgene (USA).

    Techniques: Concentration Assay, Expressing, Western Blot, Software, Incubation, Immunofluorescence

    Shikonin down-regulated protein levels and inhibited enzymatic activities of STAT3-targeted molecules in melanoma cells. A375 and A2058 cells were treated with indicated concentrations of shikonin for 24 h, and then total cell lysates were collected, expression levels of (A) Mcl-1, Bcl-2, (B) MMP-2, (D) Twist, Vimentin, and N-cadherin were evaluated by Western blot analysis (left) and relative expression levels were analyzed by Image J software (right). Data were shown as mean ± SD from three independent experiments, * P < 0.05 and ** P < 0.01. (C) The enzymatic activities of MMP-2 and MMP-9 were determined by gelatinase zymography.

    Journal: Frontiers in Pharmacology

    Article Title: Inhibition of the STAT3 Signaling Pathway Contributes to the Anti-Melanoma Activities of Shikonin

    doi: 10.3389/fphar.2020.00748

    Figure Lengend Snippet: Shikonin down-regulated protein levels and inhibited enzymatic activities of STAT3-targeted molecules in melanoma cells. A375 and A2058 cells were treated with indicated concentrations of shikonin for 24 h, and then total cell lysates were collected, expression levels of (A) Mcl-1, Bcl-2, (B) MMP-2, (D) Twist, Vimentin, and N-cadherin were evaluated by Western blot analysis (left) and relative expression levels were analyzed by Image J software (right). Data were shown as mean ± SD from three independent experiments, * P < 0.05 and ** P < 0.01. (C) The enzymatic activities of MMP-2 and MMP-9 were determined by gelatinase zymography.

    Article Snippet: Constitutively active STAT3 expression construct STAT3-C Flag pRc/CMV was obtained from Addgene (USA).

    Techniques: Expressing, Western Blot, Software, Zymography

    Overexpression of STAT3 in human melanoma A375 cells reduced shikonin-mediated cell growth, migration, and invasion inhibition. A375 cells were transiently transfected with an empty vector or a STAT3C-expressing construct for 24 h, and then (A) the expression level of STAT3 in A375-STAT3C cells and A375-EV cells were examined by immunoblotting. (B–D) A375-EV or A375-STAT3C cells were incubated with shikonin for 48 h or 24 h, and then (B) cell proliferation, (C) cell migratory, and (D) cell invasive abilities were measured. Representative photographs of migrated cells (left) and quantification of these cells (right) were shown. Data were mean ± SD from three independent experiments, ## P < 0.01, * P < 0.05, and ** P < 0.01.

    Journal: Frontiers in Pharmacology

    Article Title: Inhibition of the STAT3 Signaling Pathway Contributes to the Anti-Melanoma Activities of Shikonin

    doi: 10.3389/fphar.2020.00748

    Figure Lengend Snippet: Overexpression of STAT3 in human melanoma A375 cells reduced shikonin-mediated cell growth, migration, and invasion inhibition. A375 cells were transiently transfected with an empty vector or a STAT3C-expressing construct for 24 h, and then (A) the expression level of STAT3 in A375-STAT3C cells and A375-EV cells were examined by immunoblotting. (B–D) A375-EV or A375-STAT3C cells were incubated with shikonin for 48 h or 24 h, and then (B) cell proliferation, (C) cell migratory, and (D) cell invasive abilities were measured. Representative photographs of migrated cells (left) and quantification of these cells (right) were shown. Data were mean ± SD from three independent experiments, ## P < 0.01, * P < 0.05, and ** P < 0.01.

    Article Snippet: Constitutively active STAT3 expression construct STAT3-C Flag pRc/CMV was obtained from Addgene (USA).

    Techniques: Over Expression, Migration, Inhibition, Transfection, Plasmid Preparation, Expressing, Construct, Western Blot, Incubation